Opinion

Video

Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease

Author(s):

Trinity Bivalacqua, MD, PhD,Mark D. Tyson, MD, MPH

Key opinion leaders examine the comparative safety profiles and response durations of combination therapy versus monotherapy in the treatment of BCG-unresponsive carcinoma in situ with or without papillary disease.

Video content above is prompted by the following questions:

  • Did safety outcomes with combination therapy vary from those observed with monotherapy cretostimogene or pembrolizumab?
  • Can you please talk about the duration of response and how this compares to other agents that have been tested in BCG UR CIS +/- papillary disease?
Related Videos
Interpreting ART toxicity and tolerability for bladder cancer, with Vedang Murthy, MD
Related Content
Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC
November 11th 2024

Cretostimogene grenadenorepvec plus nivolumab shows promise in cisplatin-ineligible MIBC

Hannah Clarke
"Together, the data point to the exciting potential for this combination regimen to be used to treat patients with muscle invasive bladder cancer," says Roger Li, MD.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
November 6th 2024

Expert roundtables focus on upper tract urothelial carcinoma

Urology Times staff
Two case-based roundtable discussions recently covered the advancing of care for patients with low-grade upper tract urothelial carcinoma.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
TYRA-300 shows encouraging safety, efficacy in FGFR3+ metastatic urothelial carcinoma
October 31st 2024

TYRA-300 shows encouraging safety, efficacy in FGFR3+ metastatic urothelial carcinoma

Hannah Clarke
Anti-tumor activity was observed across all patients with FGFR3-altered metastatic urothelial carcinoma who were treated at the dose levels of 90 mg and higher.
UGN-102 data published in Journal of Urology as FDA weighs NMIBC approval
October 28th 2024

UGN-102 data published in Journal of Urology as FDA weighs NMIBC approval

Hannah Clarke
The phase 3 ENVISION trial met its primary end point by demonstrating a 79.6% complete response rate at 3 months following the first instillation of the therapy.
© 2024 MJH Life Sciences

All rights reserved.